O Prause1, S Bozinovski, G P Anderson, A Lindén. 1. Lung Pharmacology Group, Department of Respiratory Medicine and Allergology, Institute of Internal Medicine, Göteborg University, Gothenburg, Sweden. olof.prause@lungall.gu.se
Abstract
BACKGROUND: The proteolytic enzyme matrix metalloproteinase (MMP)-9 can degrade structural compounds such as the extracellular matrix and the basement membrane in the airways and lungs. MMP-9 has therefore been implicated in remodelling of the airways and lungs during severe asthma and chronic obstructive pulmonary disease (COPD). METHODS: The effect of the T lymphocyte derived proinflammatory cytokine interleukin (IL)-17 on MMP-9 protein release and activity in the airways was studied in vivo and in vitro. RESULTS: In vivo, intranasal stimulation of mice with IL-17 induced the release of the precursor molecule proMMP-9 in bronchoalveolar lavage (BAL) fluid, associated with a pronounced local accumulation of neutrophils that stained positive for MMP-9. Stimulation with IL-17 also increased the concentration of free soluble MMP-9 that was proteolytically active as determined by a gelatinase substrate assay. The concentration of MMP-9 in BAL fluid had a strong positive correlation with the number of neutrophils; the amount of MMP-9 per neutrophil was not increased by IL-17 stimulation. In vitro, stimulation of mouse neutrophils with IL-17 did not increase the concentration of proMMP-9 in the conditioned medium. CONCLUSION: Local stimulation with IL-17 increases the concentration of biologically active MMP-9 as well as its precursor molecule in mouse airways in vivo. This increase in proteolytic load is probably mainly due to an increased number of neutrophils and not to an increase in the release of MMP-9 from each neutrophil. These findings indicate a link between the T lymphocyte cytokine IL-17 and increased proteolytic load in the airways which may be relevant for chronic inflammatory airway diseases such as severe asthma and COPD.
BACKGROUND: The proteolytic enzyme matrix metalloproteinase (MMP)-9 can degrade structural compounds such as the extracellular matrix and the basement membrane in the airways and lungs. MMP-9 has therefore been implicated in remodelling of the airways and lungs during severe asthma and chronic obstructive pulmonary disease (COPD). METHODS: The effect of the T lymphocyte derived proinflammatory cytokine interleukin (IL)-17 on MMP-9 protein release and activity in the airways was studied in vivo and in vitro. RESULTS: In vivo, intranasal stimulation of mice with IL-17 induced the release of the precursor molecule proMMP-9 in bronchoalveolar lavage (BAL) fluid, associated with a pronounced local accumulation of neutrophils that stained positive for MMP-9. Stimulation with IL-17 also increased the concentration of free soluble MMP-9 that was proteolytically active as determined by a gelatinase substrate assay. The concentration of MMP-9 in BAL fluid had a strong positive correlation with the number of neutrophils; the amount of MMP-9 per neutrophil was not increased by IL-17 stimulation. In vitro, stimulation of mouse neutrophils with IL-17 did not increase the concentration of proMMP-9 in the conditioned medium. CONCLUSION: Local stimulation with IL-17 increases the concentration of biologically active MMP-9 as well as its precursor molecule in mouse airways in vivo. This increase in proteolytic load is probably mainly due to an increased number of neutrophils and not to an increase in the release of MMP-9 from each neutrophil. These findings indicate a link between the T lymphocyte cytokine IL-17 and increased proteolytic load in the airways which may be relevant for chronic inflammatory airway diseases such as severe asthma and COPD.
Authors: S Molet; Q Hamid; F Davoine; E Nutku; R Taha; N Pagé; R Olivenstein; J Elias; J Chakir Journal: J Allergy Clin Immunol Date: 2001-09 Impact factor: 10.793
Authors: D V Jovanovic; J Martel-Pelletier; J A Di Battista; F Mineau; F C Jolicoeur; M Benderdour; J P Pelletier Journal: Arthritis Rheum Date: 2000-05
Authors: P Ye; P B Garvey; P Zhang; S Nelson; G Bagby; W R Summer; P Schwarzenberger; J E Shellito; J K Kolls Journal: Am J Respir Cell Mol Biol Date: 2001-09 Impact factor: 6.914
Authors: Steven Bozinovski; Ross Vlahos; Desiree Anthony; Jonathan McQualter; Gary Anderson; Louis Irving; Daniel Steinfort Journal: Br J Pharmacol Date: 2015-07-08 Impact factor: 8.739
Authors: Patricia R Taylor; Sanhita Roy; Evan C Meszaros; Yan Sun; Scott J Howell; Charles J Malemud; Eric Pearlman Journal: J Leukoc Biol Date: 2016-03-31 Impact factor: 4.962
Authors: Hui-Leng Tan; Nicolas Regamey; Sarah Brown; Andrew Bush; Clare M Lloyd; Jane C Davies Journal: Am J Respir Crit Care Med Date: 2011-04-07 Impact factor: 21.405